Clinical Trial Update: A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating venetoclax in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2023-08-22